Standout Papers

TVB-2640 (FASN Inhibitor) for the Treatment of Nonalcoholic Steatohepatitis: FASCINATE-1, a Randomized, Placebo-C... 2021 2026 2022 2024152
  1. TVB-2640 (FASN Inhibitor) for the Treatment of Nonalcoholic Steatohepatitis: FASCINATE-1, a Randomized, Placebo-Controlled Phase 2a Trial (2021)
    Rohit Loomba, Rizwana Mohseni et al. Gastroenterology
  2. Effect of pemvidutide, a GLP-1/glucagon dual receptor agonist, on MASLD: A randomized, double-blind, placebo-controlled study (2024)
    Stephen A. Harrison, Sarah Browne et al. Journal of Hepatology

Immediate Impact

21 by Nobel laureates 28 from Science/Nature 56 standout
Sub-graph 1 of 22

Citing Papers

Aspirin for Metabolic Dysfunction–Associated Steatotic Liver Disease Without Cirrhosis
2024 Standout
Tumor-infiltrating regulatory T cells as targets of cancer immunotherapy
2023 StandoutNobel

Works of Julio Gutiérrez being referenced

TVB-2640 (FASN Inhibitor) for the Treatment of Nonalcoholic Steatohepatitis: FASCINATE-1, a Randomized, Placebo-Controlled Phase 2a Trial
2021 Standout
Disruption of the CCL1-CCR8 axis inhibits vascular Treg recruitment and function and promotes atherosclerosis in mice
2019

Author Peers

Author Last Decade Papers Cites
Julio Gutiérrez 710 861 716 907 81 2.7k
Kenji Kaneda 1036 960 1168 998 127 3.6k
Fang Guo 357 774 916 582 95 2.6k
Franco M. Buonaguro 244 1138 1294 720 108 3.3k
Asish K. Ghosh 622 559 1503 574 108 3.1k
G A Currie 282 497 1349 1428 70 4.0k
Haizhen Zhu 741 707 1262 824 84 2.9k
Christoph Neumann‐Haefelin 2261 1756 580 1687 110 3.9k
Christine Neuveut 802 1395 2007 866 53 3.8k
Cristina Maria Failla 903 667 1165 453 58 2.8k
Yan‐Hwa Wu Lee 989 972 1739 314 82 3.1k

All Works

Loading papers...

Rankless by CCL
2026